Thelen Patrick, Böhringer Daniel, Keye Philip, Reinhard Thomas, Lübke Jan
Department of Ophthalmology, University Medical Center Freiburg, Faculty of Medicine, Albert Ludwig University of Freiburg, 79106 Freiburg, Germany.
Biomedicines. 2024 Sep 27;12(10):2212. doi: 10.3390/biomedicines12102212.
BACKGROUND/OBJECTIVES: Recent prospective studies have shown that selective laser tra-beculoplasty (SLT) is a safe and cost-effective alternative to pressure-reducing eye drop therapy as a first-line treatment for ocular hypertension or open-angle glaucoma. In addition to its comparable efficacy to eye drop therapy, SLT has been particularly effective in delaying the time until a surgical intervention is needed. The aim of our evaluation is to analyze patients who have received SLT following a pressure-reducing procedure. The primary endpoint is the duration until a subsequent interventional or surgical procedure is required.
A retrospective analysis of 98 patients who underwent selective laser trabeculoplasty following a previous pressure-reducing procedure between 2017 and 2023. The statistical analyses included Cox regression and Kaplan-Meier survival estimations.
In total, 122 eyes of 98 patients received selective laser trabeculoplasty following a previous pressure-reducing procedure at the Department of Ophthalmology in Freiburg. The median follow-up period was 381.5 days (range 43.25-862.75 days). Approximately 68% of the eyes did not require another pressure-reducing procedure 365 days after the intervention, while about 58% of the eyes remained without another procedure after 730 days, according to Kaplan-Meier analysis. No significant difference was found between the different types of glaucoma regarding the duration until a subsequent pressure-reducing procedure was needed. The study indicated a tendency for patients with pseudoexfoliation glaucoma to undergo a secondary intervention earlier compared to those with primary open-angle glaucoma ( = 0.16). The intraocular pressure before SLT had a significant impact on the duration until the subsequent operation ( = 0.005).
SLT is an effective method even after a previous pressure-reducing procedure for patients in whom further pressure-reducing interventions need to be delayed.
背景/目的:近期的前瞻性研究表明,选择性激光小梁成形术(SLT)作为眼压升高或开角型青光眼的一线治疗方法,是一种安全且具有成本效益的替代降压眼药水治疗的方法。除了与眼药水治疗具有相当的疗效外,SLT在延迟手术干预所需时间方面特别有效。我们评估的目的是分析接受降压手术后接受SLT治疗的患者。主要终点是直到需要进行后续介入或手术的持续时间。
对2017年至2023年间在先前降压手术后接受选择性激光小梁成形术的98例患者进行回顾性分析。统计分析包括Cox回归和Kaplan-Meier生存估计。
在弗莱堡眼科医院,共有98例患者的122只眼睛在先前的降压手术后接受了选择性激光小梁成形术。中位随访期为381.5天(范围43.25 - 862.75天)。根据Kaplan-Meier分析,约68%的眼睛在干预后365天不需要再次进行降压手术,而约58%的眼睛在730天后仍无需再次手术。在不同类型青光眼之间,直到需要进行后续降压手术的持续时间没有发现显著差异。研究表明,与原发性开角型青光眼患者相比,剥脱性青光眼患者有更早接受二次干预的趋势(P = 0.16)。SLT前的眼压对直到后续手术的持续时间有显著影响(P = 0.005)。
对于需要延迟进一步降压干预的患者,即使在先前的降压手术后,SLT也是一种有效的方法。